Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial.

Angiolillo DJ, Welsh RC, Trenk D, Neumann FJ, Conley PB, McClure MW, Stephens G, Kochman J, Jennings LK, Gurbel PA, Wójcik J, Dabrowski M, Saucedo JF, Stumpf J, Buerke M, Broderick S, Harrington RA, Rao SV.

Circ Cardiovasc Interv. 2012 Jun;5(3):347-56. doi: 10.1161/CIRCINTERVENTIONS.111.965608. Epub 2012 May 22.

2.

A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.

Welsh RC, Rao SV, Zeymer U, Thompson VP, Huber K, Kochman J, McClure MW, Gretler DD, Bhatt DL, Gibson CM, Angiolillo DJ, Gurbel PA, Berdan LG, Paynter G, Leonardi S, Madan M, French WJ, Harrington RA; INNOVATE-PCI Investigators.

Circ Cardiovasc Interv. 2012 Jun;5(3):336-46. doi: 10.1161/CIRCINTERVENTIONS.111.964197. Epub 2012 May 29.

3.

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI).

Leonardi S, Rao SV, Harrington RA, Bhatt DL, Gibson CM, Roe MT, Kochman J, Huber K, Zeymer U, Madan M, Gretler DD, McClure MW, Paynter GE, Thompson V, Welsh RC.

Am Heart J. 2010 Jul;160(1):65-72. doi: 10.1016/j.ahj.2010.04.008.

PMID:
20598974
4.

Rapid P2Y12 inhibition: still an unmet medical need.

Silvain J, Montalescot G.

Circ Cardiovasc Interv. 2012 Jun;5(3):328-31. doi: 10.1161/CIRCINTERVENTIONS.112.970319. No abstract available.

5.

Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.

Angiolillo DJ, Schneider DJ, Bhatt DL, French WJ, Price MJ, Saucedo JF, Shaburishvili T, Huber K, Prats J, Liu T, Harrington RA, Becker RC.

J Thromb Thrombolysis. 2012 Jul;34(1):44-55. doi: 10.1007/s11239-012-0737-3.

PMID:
22569899
6.

Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.

Sardella G, Calcagno S, Mancone M, Palmirotta R, Lucisano L, Canali E, Stio RE, Pennacchi M, Di Roma A, Benedetti G, Guadagni F, Biondi-Zoccai G, Fedele F.

Circ Cardiovasc Interv. 2012 Oct;5(5):698-704. doi: 10.1161/CIRCINTERVENTIONS.112.972463. Epub 2012 Oct 9.

7.
8.

The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.

Gurbel PA, Bliden KP, Antonino MJ, Stephens G, Gretler DD, Jurek MM, Pakyz RE, Shuldiner AR, Conley PB, Tantry US.

J Thromb Haemost. 2010 Jan;8(1):43-53. doi: 10.1111/j.1538-7836.2009.03648.x. Epub 2009 Oct 11.

10.

Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans.

Cushing DJ, Souney PF, Cooper WD, Mosher GL, Adams MP, Machatha S, Zhang B, Kowey PR.

Clin Exp Pharmacol Physiol. 2012 Jan;39(1):3-8. doi: 10.1111/j.1440-1681.2011.05616.x.

PMID:
21933229
11.

Elinogrel, an orally and intravenously available ADP-receptor antagonist. How does elinogrel affect a personalized antiplatelet therapy?

Müller KA, Geisler T, Gawaz M.

Hamostaseologie. 2012;32(3):191-4. doi: 10.5482/ha-1192. Epub 2012 Jul 5.

PMID:
22772894
12.

Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.

Capranzano P, Mehran R, Tamburino C, Stone GW, Dangas G.

Hosp Pract (1995). 2010 Nov;38(4):38-43. doi: 10.3810/hp.2010.11.338.

PMID:
21068525
13.

Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.

Small DS, Payne CD, Kothare P, Yuen E, Natanegara F, Teng Loh M, Jakubowski JA, Richard Lachno D, Li YG, Winters KJ, Farid NA, Ni L, Salazar DE, Tomlin M, Kelly R.

Clin Ther. 2010 Feb;32(2):365-79. doi: 10.1016/j.clinthera.2010.02.015.

PMID:
20206794
14.

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.

Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G.

Circ Cardiovasc Interv. 2012 Dec;5(6):797-804. doi: 10.1161/CIRCINTERVENTIONS.112.972323. Epub 2012 Nov 20.

15.
16.
17.

Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond.

Serebruany VL, Sibbing D, DiNicolantonio JJ.

Cardiology. 2014;127(1):20-4. doi: 10.1159/000354876. Epub 2013 Oct 26. Review.

PMID:
24192670
18.

Clinical effects and outcomes with new P2Y12 inhibitors in ACS.

Collet JP, O'Connor S.

Fundam Clin Pharmacol. 2012 Feb;26(1):16-8. doi: 10.1111/j.1472-8206.2011.00984.x. Epub 2011 Sep 5. Review.

PMID:
21895760
19.

[Myocardial infarction: Role of new antiplatelet agents].

Silvain J, Bellemain A, Ecollan P, Montalescot G, Collet JP.

Presse Med. 2011 Jun;40(6):615-24. doi: 10.1016/j.lpm.2011.03.002. Epub 2011 Apr 20. Review. French.

PMID:
21511430
20.

High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study.

Chirumamilla AP, Maehara A, Mintz GS, Mehran R, Kanwal S, Weisz G, Hassanin A, Hakim D, Guo N, Baber U, Pyo R, Moses JW, Fahy M, Kovacic JC, Dangas GD.

JACC Cardiovasc Imaging. 2012 May;5(5):540-9. doi: 10.1016/j.jcmg.2011.12.019.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk